Roche Development Pipeline 2022 | Drug Portfolio Update

Comprehensive overview of Roche's pharmaceutical development pipeline as of July 2022, detailing all marketed products and development programs across multiple therapeutic areas including oncology, immunology, neuroscience, and ophthalmology. The presentation documents 49 new molecular entities in Phase I, 22 in Phase II, and recent regulatory approvals and pipeline transitions for the first half of 2022.